Related Experiment Videos
Therapeutic application of anti-growth factor receptor antibodies
1Department of Clinical Investigation, The University of Texas, M.D. Anderson Cancer Center, Houston 77030-4095, USA.
Abstract:
The application of monoclonal antibodies for the treatment of human cancer has been under extensive study for nearly two decades. With the advent of recombinant antibody technology, which makes humanized antibody or human-mouse chimeric antibody available for clinical trials, significant progress has been made in the past several years. In this article, we present an overview of recent research on anti-growth factor receptor antibodies. This research aims to modulate the function of growth factor receptors or to exploit the overexpression of these receptors on cancer cells for targeted therapy. The pharmacologic blockade of receptors with antireceptor antibody has been explored as anticancer therapy, both alone and in combination with conventional chemotherapy, or with novel inhibitors acting on various steps of signal transduction pathways. There also has been progress in research on intracellular antibodies, bispecific antibodies, antibody-fusion molecules, and antireceptor antibodies as a means of nonviral gene therapy. This review focuses primarily on monoclonal antibodies directed against the epidermal growth factor receptor family.
Insights
Monoclonal antibodies targeting growth factor receptors show promise for cancer therapy. Research explores their use alone, with chemotherapy, or novel inhibitors for improved cancer treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Monoclonal antibody therapy for human cancer has been researched for nearly two decades.
- Recombinant antibody technology has enabled clinical trials of humanized and chimeric antibodies.
- Significant advancements in antibody-based cancer treatments have occurred recently.
Purpose of the Study:
- To provide an overview of recent research on anti-growth factor receptor antibodies.
- To explore the modulation of growth factor receptor function for cancer therapy.
- To review the use of antibodies targeting overexpressed receptors on cancer cells for targeted therapy.
Main Methods:
- Review of research on monoclonal antibodies targeting growth factor receptors.
- Exploration of pharmacologic blockade of receptors with antireceptor antibodies.
- Investigation of combination therapies including conventional chemotherapy and signal transduction inhibitors.
Main Results:
- Progress in developing intracellular antibodies, bispecific antibodies, and antibody-fusion molecules.
- Advancements in antireceptor antibodies for nonviral gene therapy applications.
- Focus on monoclonal antibodies targeting the epidermal growth factor receptor family.
Conclusions:
- Anti-growth factor receptor antibodies represent a significant area of cancer therapy research.
- These antibodies can be used alone, in combination therapies, or for targeted delivery.
- Further research is ongoing for various antibody formats and therapeutic strategies.